Paul Joseph Dyson, Christian Hartinger, Michael Groessl
A review. The promising drug candidate indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) is the second Ru-based anticancer agent to enter clin. trials. In this review, which is an update of a paper from 2006, the exptl. evidence for the ...
2008